NeoGenomics (NEO) said Monday it has closed the acquisition of New Jersey-based laboratory Pathline.
Financial terms were not disclosed.
The acquisition supports NeoGenomics' commercial presence in the Northeast US and its growth in molecular and hematology-oncology testing, the company said.